SFXN2 and plasma cell myeloma: Elevated SFXN2 correlates with poor clinical outcomes in multiple myeloma and acute myeloid leukemia, potentially due to its regulations of mitochondrial iron metabolism, bioenergetics, autophagy, and redox homeostasis (Chen Y. et al., 2022).